Responses
Regular and Young Investigator Award Abstracts
Clinical Trials Completed
600 Post-hoc analysis from two phase I/II NY-ESO-1-TCR T-cell therapy clinical trials in patients with advanced sarcoma (SS or MRCLS) demonstrates response across a range of NY-ESO-1 expression
Compose a Response to This Article
Other responses
No responses have been published for this article.